FDA Warns California Drugmaker for Sourcing from Sub-Standard CMOs

Drug Industry Daily
A A
The FDA issued a warning letter to United Exchange Corp. for serious quality violations, including using products from “multiple sub-standard contract manufacturers” at its Cypress and Rialto drug manufacturing plants.

To View This Article:

Login

Subscribe To Drug Industry Daily